Company Directory > Biotech > Cobel Darou
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cobel Darou and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Cobel Darou is a prominent private pharmaceutical company headquartered in Tehran, Iran, established in 2001. The company specializes in the research, registration, importation, manufacturing, marketing, and distribution of a wide range of specialized and general prescription medicines. It plays a significant role in the Iranian pharmaceutical market by collaborating with international partners to provide access to advanced therapies. Beyond its core commercial activities, the company is the largest shareholder of Dr. Abidi Pharmaceutical Company and the founder of AdoraTeb Distribution Company, creating a robust operational network. Cobel Darou focuses on critical therapeutic areas including cardiovascular diseases, oncology, diabetes, central nervous system disorders, and vaccines, while maintaining a strong commitment to social responsibility and public health initiatives.
CLASSIFICATION
Company Type:Biotech
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals
SIZE & FINANCIALS
Employees:201-500
Revenue:$50M-$100M
Founded:2001
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biological agents
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Dr. Abidi Pharmaceutical Company (Largest Shareholder), AdoraTeb Distribution Company
Key Partnerships:Sanofi, Roche Diabetes Care, GSK, AstraZeneca
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Amir Hashemi - CEO
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cobel Darou. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.